000 01435 a2200409 4500
005 20250518012157.0
264 0 _c20190702
008 201907s 0 0 eng d
022 _a1474-4457
024 7 _a10.1016/S1473-3099(18)30610-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRegan, David G
245 0 0 _aTreatment for pharyngeal gonorrhoea under threat.
_h[electronic resource]
260 _bThe Lancet. Infectious diseases
_c11 2018
300 _a1175-1177 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnti-Bacterial Agents
_xadministration & dosage
650 0 4 _aAzithromycin
_xadministration & dosage
650 0 4 _aCeftriaxone
_xadministration & dosage
650 0 4 _aComputer Simulation
650 0 4 _aDisease Transmission, Infectious
650 0 4 _aDrug Resistance, Bacterial
650 0 4 _aFemale
650 0 4 _aGonorrhea
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aNeisseria meningitidis
_xdrug effects
650 0 4 _aPharyngitis
_xdrug therapy
650 0 4 _aTreatment Outcome
700 1 _aHui, Ben B
700 1 _aWood, James G
700 1 _aFifer, Helen
700 1 _aLahra, Monica M
700 1 _aWhiley, David M
773 0 _tThe Lancet. Infectious diseases
_gvol. 18
_gno. 11
_gp. 1175-1177
856 4 0 _uhttps://doi.org/10.1016/S1473-3099(18)30610-8
_zAvailable from publisher's website
999 _c29121264
_d29121264